TRDX Announces Signing of Definitive Agreement With Genesis Biopharma, Inc. to Acquire an Exclusive Worldwide Sublicense for a D
23 Agosto 2010 - 3:30PM
Marketwired
SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or
the "Company") (PINKSHEETS: TRDX) today announces it has recently
executed a Definitive Sublicense Agreement with Montreal-based
Genesis Bio Pharma, Inc. to acquire the exclusive worldwide
sublicense for a new compound in development for the treatment of
Painful Diabetic Neuropathy (PDN).
ABOUT PDN:
PDN is one of many complications of diabetes. Forty to fifty
percent of diabetic patients may develop PDN over 15 to 20 years.
PDN is present in 11.6% of patients with Type I diabetes and 32.1%
of patients with Type II diabetes. PDN may present itself as a
progressive build-up of unpleasant sensory symptoms including
tingling (paraesthesia), burning pain, radiating pain down the legs
and toes and lancinating or contact pain. The pain is more severe
during the night and often prevents sleep. Some patients may be in
a constant state of tiredness because of sleep deprivation while
others are unable to maintain employment.
Dr. Jan Stahl, CEO of TRDX, commented: "The signing of this
Definitive Agreement is a major achievement for the development of
our partnership with Genesis. We look forward to the closing and
working with Genesis to continue the groundbreaking development to
treat diabetic neuropathy."
Mr. Leo Stella, CEO of GENESIS Bio Pharma Inc., commented: "We
are pleased with the signing of this Agreement and now look forward
to the closing so we can move quickly to reach our goals by
commencing the clinical trials as soon as possible."
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian
corporation founded in 2007 to exploit the commercial potential for
the therapeutic use of peptidomimetic (modified amino acid
peptides) compounds. Amino acids are the building blocks of
proteins, which are found in every cell. Proteins consist of
extremely long and complex amino acid chains. In contrast, a
peptide is a short string of amino acids, joined by chemical bonds
(also called "amide bonds").
About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS:
TRDX)
SciMeDent is a company focused on being a leading developer and
marketer of products and services for medicine, dentistry and life
sciences. SciMeDent plans to achieve growth initially through
mergers and acquisitions.
Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are
forward-looking statements. These forward-looking statements
involve a number of risks and uncertainties, including the
sufficiency of existing capital resources, technological or
industry changes and uncertainties related to the development of
the Company's business model. The actual results the Company may
achieve could differ materially from any forward-looking statements
due to such risks and uncertainties.
Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc.
dmyers@cadenceconsultingllc.com 1-866-383-1374
Trend Exploration (PK) (USOTC:TRDX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Trend Exploration (PK) (USOTC:TRDX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024